{"nctId":"NCT04223479","briefTitle":"Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan","startDateStruct":{"date":"2020-01-15","type":"ACTUAL"},"conditions":["Ulcerative Colitis"],"count":30,"armGroups":[{"label":"Probiotic Formula Capsule","type":"EXPERIMENTAL","interventionNames":["Drug: Probiotic Formula Capsule"]},{"label":"Placebos","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebos"]}],"interventions":[{"name":"Probiotic Formula Capsule","otherNames":["Probiotics capsule","Probiotics supplement"]},{"name":"Placebos","otherNames":["Placebo oral capsule"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female patients,\n* Age between 35 -65 years,\n* Diagnosed with UC established by colonoscopy and histology, and suffering from mild to moderate UC as defined by Modified Mayo Disease Activity Index (MMDAI) (score 3-9).\n\nExclusion Criteria:\n\n* Patients with age \\<35 years, \\>65 years,\n* Pregnancy, planned pregnancy, breastfeeding women,\n* Evidence of severe disease (MMDAI \\>10),\n* Concurrent enteric infection,\n* Use of antibiotics,\n* Change in the dose of oral 5-aminosalicylic acid (5-ASA) within the past 4weeks, and use of rectal 5-ASA or steroids within 7 days before entry into the study,\n* Received any investigational medicines within 3months,\n* If they have significant hepatic, renal, endocrine, respiratory, neurological, or cardiovascular diseases","healthyVolunteers":true,"sex":"ALL","minimumAge":"35 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Level of Immunoglobulin (Ig) A","description":"The level of Immunoglobulin (Ig) A in mg/dL was tested at the end of follow-up (after 6 weeks of follow-up) based on an Immunoturbidimetric assay using Cobas-C501","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"270.42","spread":"71.79"},{"groupId":"OG001","value":"208.63","spread":"85.84"}]}]}]},{"type":"PRIMARY","title":"The Level of Immunoglobulin (Ig) G","description":"The level of Immunoglobulin (Ig) G in mg/dL was tested at the end of follow-up (after 6 weeks of follow-up) based on an Immunoturbidimetric assay using Cobas-C501","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1267.36","spread":"177.6"},{"groupId":"OG001","value":"1214.70","spread":"236.3"}]}]}]},{"type":"PRIMARY","title":"The Level of Immunoglobulin (Ig) M","description":"The level of Immunoglobulin (Ig) M in mg/dL was tested at the end of follow-up (after 6 weeks of follow-up) based on an Immunoturbidimetric assay using Cobas-C501","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114.64","spread":"62.03"},{"groupId":"OG001","value":"104.10","spread":"39.57"}]}]}]},{"type":"PRIMARY","title":"The Level of Interleukin (IL)-6","description":"The Level of Interleukin (IL)-6 in pg/ml measured aat the end of follow-up (after 6 weeks of follow-up) by a two-site sandwich Enzyme-Linked Immunosorbent Assay (ELISA)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.84","spread":"3.30"},{"groupId":"OG001","value":"9.40","spread":"3.13"}]}]}]},{"type":"PRIMARY","title":"The Level of Interleukin (IL)-1","description":"The Level of Interleukin (IL)-1 in pg/ml measured at the end of follow-up (after 6 weeks of follow-up) by a two-site sandwich Enzyme-Linked Immunosorbent Assay (ELISA)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.33","spread":"3.31"},{"groupId":"OG001","value":"8.55","spread":"3.45"}]}]}]},{"type":"PRIMARY","title":"The Level of Interleukin (IL)-10","description":"The Level of Interleukin (IL)-10 in pg/ml was measured at the end of follow-up (after 6 weeks of follow-up) by a two-site sandwich Enzyme-Linked Immunosorbent Assay (ELISA)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.89","spread":"12.49"},{"groupId":"OG001","value":"37.10","spread":"14.95"}]}]}]},{"type":"PRIMARY","title":"The Level of Tumor Necrosis Factor (TNF)-α","description":"The Level of TNF-α in pg/ml measured at the end of follow-up (after 6 weeks of follow-up) by a two-site sandwich Enzyme-Linked Immunosorbent Assay (ELISA)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.36","spread":"1.57"},{"groupId":"OG001","value":"9.58","spread":"1.75"}]}]}]},{"type":"PRIMARY","title":"The Level of C-reactive Protein (CRP)","description":"The Level of CRP in mg/ml measured at the end of follow-up (after 6 weeks of follow-up) based on an Immunoturbidimetric assay using Cobas-C501","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.65","spread":"0.24"},{"groupId":"OG001","value":"4.54","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Quality of Life of Patients","description":"The average score of the general quality of life (QoL) subscales was assessed by the Short Quality of Life in Inflammatory Bowel Disease Questionnaire (SIBDQ). The SIBDQ contains 10 questions for 4 functional scales (Bowel, Systemic, emotional, and social). For each question, there a regraded responses on a 7-point Likert scale ranging from one (representing the ''worst'' aspect) to seven (representing the ''best'' aspect). Total SIBDQ scores range from 10 to 70.Higher scores reflect better well-being.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.96","spread":"1.27"},{"groupId":"OG001","value":"6.54","spread":"0.29"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Level of White Blood Cell Count (WBC)","description":"The level of WBC as cells\\*10\\^9/l measured at the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.18","spread":"2.90"},{"groupId":"OG001","value":"6.72","spread":"2.01"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Level of Red Blood Cell Count (RBC)","description":"The level of RBC as cells\\*10\\^12/l measured at the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.73","spread":"0.55"},{"groupId":"OG001","value":"4.95","spread":"0.36"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Mean Corpuscular Volume (MCV)","description":"The MCV in fl measured at the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.68","spread":"9.23"},{"groupId":"OG001","value":"83.63","spread":"7.33"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Mean Corpuscular Hemoglobin (MCH)","description":"The MCH in pg measured at the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.70","spread":"3.27"},{"groupId":"OG001","value":"27.88","spread":"2.96"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Mean Corpuscular Hemoglobin Concentration (MCHC)","description":"The MCH in g/dl measured at the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.28","spread":"0.90"},{"groupId":"OG001","value":"33.52","spread":"1.31"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Platelet Count","description":"The Platelet count as cells 10\\^9/ll measured at the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"292.40","spread":"72.05"},{"groupId":"OG001","value":"288.18","spread":"69.47"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The of Hemoglobin","description":"The Hemoglobin in g/dl measured at the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.54","spread":"2.01"},{"groupId":"OG001","value":"13.78","spread":"1.54"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Mean Platelet Volume (MPV)","description":"The MPV in fl measured at the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.67","spread":"1.22"},{"groupId":"OG001","value":"10.71","spread":"0.83"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Level of Lymphocytes","description":"The number of lymphocytes cells as cells\\*10\\^9/L measuredat the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.50","spread":"0.93"},{"groupId":"OG001","value":"2.40","spread":"0.69"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Level of Monocytes","description":"The number of Monocytes cells measured at the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.28"},{"groupId":"OG001","value":"0.59","spread":"0.16"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Level of Eosinophils","description":"The number of eosinophils cells measured at the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.19"},{"groupId":"OG001","value":"0.15","spread":"0.10"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Level of Basophils","description":"The number of basophils cells measured at the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Level of Neutrophils","description":"The number of neutrophils cells measured at the end of follow-up (after 6 weeks of follow-up) using the automated analyzer Sysmex XS-500i","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.05","spread":"2.35"},{"groupId":"OG001","value":"3.56","spread":"1.59"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":[]}}}